Vonvendi
About Vonvendi
Vonvendi is a Healthcare company, and was acquired by Barings in June 2018. Recombinant von Willebrand factor treatment is manufactured for adults. Its focus areas include Pharmaceutical Product Websites. Its legal entity is Takeda Pharmaceuticals U.S.A., Inc.
Company details
Manufacturer of recombinant von Willebrand factor treatment for adults with von Willebrand disease. This treatment is used to manage bleeding episodes, prevent excessive bleeding during and after surgery, and reduce the frequency of bleeding episodes in patients with severe Type 3 von Willebrand disease. The product is manufactured without human blood or plasma, minimizing the risk of bloodborne disease transmission. It can be used with or without recombinant FVIII as directed by a healthcare provider. The treatment addresses a specific unmet need in managing this inherited bleeding disorder.
Apps and channels of Vonvendi
its YouTube channel Takeda has 23.8K subscribers and 30 videos.
Videos from Vonvendi
The most watched videos on Vonvendi's YouTube channel, Takeda (23.8K subscribers). Click a video to play it here.
More on Takeda.
Investors in Vonvendi
Vonvendi has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include Barings.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Private fund focused on debt and equity investments in real estate and multiple sectors | 1762 | barings.com | London, United Kingdom |
Investor details for Vonvendi
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Web traffic of Vonvendi
The website of Vonvendi (vonvendi.com) receives about 5.7K visits a month.
- Monthly visits5.7K
▼ 30.9% vs previous month
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Vonvendi
Manufacturer of recombinant von Willebrand factor treatment for adults with von Willebrand disease. This treatment is used to manage bleeding episodes, prevent excessive bleeding during and after surgery, and reduce the frequency of bleeding episodes in patients with severe Type 3 von Willebrand disease. The product is manufactured without human blood or plasma, minimizing the risk of bloodborne disease transmission. It can be used with or without recombinant FVIII as directed by a healthcare provider. The treatment addresses a specific unmet need in managing this inherited bleeding disorder.
Vonvendi has 1 investor. Key investors include Barings.
Vonvendi operates through Takeda Pharmaceuticals U.S.A., Inc.
Yes. Vonvendi was acquired by Barings in June 2018.